MorphoSys’ pelabresib meets endpoints in Phase III myelofibrosis trial

MorphoSys has reported positive topline results from the Phase III MANIFEST-2 clinical trial investigating pelabresib in myelofibrosis.

The trial evaluated pelabresib in combination with Novartis and Incyte’s Jakafi (ruxolitinib). compared to placebo plus Jakafi in JAK inhibitor-naïve patients with myelofibrosis.